Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com

0001062993-19-001598.txt : 20190408 0001062993-19-001598.hdr.sgml : 20190408 20190408070649 ACCESSION NUMBER: 0001062993-19-001598 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20190408 FILED AS OF DATE: 20190408 DATE AS OF CHANGE: 20190408 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Trillium Therapeutics Inc. CENTRAL INDEX KEY: 0001616212 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1214 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36596 FILM NUMBER: 19736377 BUSINESS ADDRESS: STREET 1: 2488 DUNWIN DRIVE CITY: MISSISSAUGA STATE: A6 ZIP: L5L 1J9 BUSINESS PHONE: (416) 595-0627 MAIL ADDRESS: STREET 1: 2488 DUNWIN DRIVE CITY: MISSISSAUGA STATE: A6 ZIP: L5L 1J9 6-K 1 form6k.htm FORM 6-K Trillium Therapeutics Inc. - Form 6-K - Filed by newsfilecorp.com

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

___________________

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2019

Commission File Number: 001-36596

___________________

TRILLIUM THERAPEUTICS INC.
(Translation of registrant's name into English)

2488 Dunwin Drive
Mississauga, Ontario L5L 1J9
Canada
(Address of principal executive offices)
___________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [X] Form 40-F [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)[ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)[ ]

DOCUMENTS FILED AS PART OF THIS FORM 6-K

See the Exhibit Index hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Trillium Therapeutics Inc.


Date: April 8, 2019
	By: /s/ James Parsons
	Name: James Parsons
	Title: Chief Financial Officer

2

EXHIBIT INDEX

Exhibit	Description

99.1	News Release dated April 8, 2019

EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Trillium Therapeutics Inc.: Exhibit 99.1 - Filed by newsfilecorp.com

FOR IMMEDIATE RELEASE	NASDAQ:TRIL
	TSX: TRIL

TRILLIUM THERAPEUTICS TO PRESENT AT INVESTOR CONFERENCES IN APRIL

TORONTO, April 8, 2019 - Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company's programs and progress at the following upcoming conferences:

Investor Conferences:

H.C. Wainwright Global Life Sciences Conference

Presenter: Dr. Niclas Stiernholm, Chief Executive Officer

Date and Time: April 9, 2019 at 3:10 p.m. BST

Location: Grosvenor House, London

18th Annual Needham Healthcare Conference

Presenter: Dr. Bob Uger, Chief Scientific Officer

Date and Time: April 10, 2019 at 12:00 p.m. ET

Location: Westin Grand Central Hotel, New York City

A live audio webcast of the H.C. Wainwright Global Life Sciences Conference presentation will be available under the investor relations section of Trillium's website at www.trilliumtherapeutics.com.

About Trillium Therapeutics

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company's two clinical programs, TTI-621 and TTI-622, target CD47, a "do not eat" signal that cancer cells frequently use to evade the immune system.

Trillium also has a preclinical STING program and a proprietary fluorine-based medicinal chemistry platform that is being used to develop novel compounds directed at undisclosed immuno-oncology targets.

For more information visit: www.trilliumtherapeutics.com

Contact and Investor Relations:

James Parsons

Chief Financial Officer

Trillium Therapeutics Inc.

416-595-0627 x232

james@trilliumtherapeutics.com

Media Relations:

Jessica Tieszen
Canale Communications for Trillium Therapeutics
619-849-5385

jessica@canalecomm.com

-2-

GRAPHIC 3 a79a163fd44-001.jpg GRAPHIC begin 644 a79a163fd44-001.jpg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end